Founder & Research Director

Professor Nikolai Petrovsky

Professor Nikolai Petrovsky, Vaxine’s founder and Research Director, is a world-renowned expert in vaccine development and immunology.

He has published over 200 peer-reviewed original research papers as well as many reviews and book chapters and has won multiple awards and prizes including a 2010 Ernst and Young Entrepreneur of the Year Award, and 2013 BioPharma Asian Executive of the Year Award.

He is an inventor on multiple vaccine patents and has been awarded over 50 million dollars in vaccine grants including from US and Australian government funding bodies. 

He developed Covax-19/SpikoGen® vaccine that was approved for use in Iran in October 2021, becoming the first successful human vaccine developed in Australia in the last 40 years.

Business Manager

Sharen Pringle

Sharen started as Business Manager at the National Health Science Centre in 1998 and joined Vaxine Pty Ltd in 2002 in the role of Clinical Trials Manager after completing a Graduate Certificate in Clinical Trial Management at the University of Canberra. Sharen managed 14 trials in the area of Diabetes and Cardiovascular disease during her appointment at NHSC and Vaxine in Canberra, ACT.

Vaxine moved to South Australia in 2004 where Sharen established a successful Clinical Trial Unit, its main purpose being to trial vaccines developed by Vaxine Pty Ltd. These vaccine trials included influenza, Swine Flu, Hepatitis B and most recently Covid-19.

Prior to joining NHSC in Canberra Sharen worked in Sales for the Sheraton Group, Federal Group and Inkeepers Group.

Join the team

Thank you for your interest.

Vaxine is a unique biotechnology company employer as our staff have a unique chance to be involved in literally every aspect of drug and vaccine development, from bench to bedside.

Vaxine interns receive training to the very highest standard across a range of scientific disciplines, and at completion of their internships are always highly sought after and have always found ready employment either with Vaxine itself or with other local or international biotechnology or pharma companies.

Senior scientific staff are given significant autonomy and have a chance to develop their careers in whatever directions they chose.

Vaxine is always on the lookout for exceptional scientists who are able to think independently and want to make a real difference to the world through their research.